# BIO-TECHNE Corp: overview

TECH · Nasdaq · CIK 842023 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/tech.md) · [Financials](/companies/tech/financials.md) · [Filings](/companies/tech/filings.md) · [Insiders](/companies/tech/insiders.md)

Latest reported revenue: [$321.2m](/filings/0001104659-26-100322.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Aug 24, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-100322).

## Last eight quarters

| Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [289](/filings/0001104659-25-107053.md) | [297](/filings/0001104659-26-010335.md) | [316](/filings/0001104659-26-056302.md) | [317 d](/filings/0001104659-26-100322.md) | [287](/filings/0001104659-25-107053.md) | [296](/filings/0001104659-26-010335.md) | [311](/filings/0001104659-26-056302.md) | [321 d](/filings/0001104659-26-100322.md) |
| Gross margin | % | [63.2%](/filings/0001104659-25-107053.md) | [65.3%](/filings/0001104659-26-010335.md) | [67.9%](/filings/0001104659-26-056302.md) | [62.7% d](/filings/0001104659-26-100322.md) | [65.6%](/filings/0001104659-25-107053.md) | [64.6%](/filings/0001104659-26-010335.md) | [66.9%](/filings/0001104659-26-056302.md) | [65.8% d](/filings/0001104659-26-100322.md) |
| Operating margin | % | [13.8%](/filings/0001104659-25-107053.md) | [16.0%](/filings/0001104659-26-010335.md) | [12.2%](/filings/0001104659-26-056302.md) | [(7.5%) d](/filings/0001104659-26-100322.md) | [16.6%](/filings/0001104659-25-107053.md) | [18.4%](/filings/0001104659-26-010335.md) | [24.2%](/filings/0001104659-26-056302.md) | [23.1% d](/filings/0001104659-26-100322.md) |
| Net margin | % | [11.6%](/filings/0001104659-25-107053.md) | [11.7%](/filings/0001104659-26-010335.md) | [7.1%](/filings/0001104659-26-056302.md) | [(5.6%) d](/filings/0001558370-25-011716.md) | [13.3%](/filings/0001104659-25-107053.md) | [12.8%](/filings/0001104659-26-010335.md) | [16.4%](/filings/0001104659-26-056302.md) | [17.0% d](/filings/0001104659-26-100322.md) |
| Diluted EPS | $ per share | [0.21](/filings/0001104659-25-107053.md) | [0.22](/filings/0001104659-26-010335.md) | [0.14](/filings/0001104659-26-056302.md) | not reported | [0.24](/filings/0001104659-25-107053.md) | [0.24](/filings/0001104659-26-010335.md) | [0.32](/filings/0001104659-26-056302.md) | not reported |
| Free cash flow | $m | [54.7](/filings/0001104659-25-107053.md) | [77.5 d](/filings/0001104659-26-010335.md) | [31.0 d](/filings/0001104659-26-056302.md) | [93.3 d](/filings/0001104659-26-100322.md) | [22.2](/filings/0001104659-25-107053.md) | [76.5 d](/filings/0001104659-26-010335.md) | [77.6 d](/filings/0001104659-26-056302.md) | [86.9 d](/filings/0001104659-26-100322.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:ProfitLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1,106](/filings/0001558370-24-012430.md) | [1,137](/filings/0001558370-25-011716.md) | [1,159](/filings/0001104659-26-100322.md) | [1,220](/filings/0001104659-26-100322.md) | [1,215](/filings/0001104659-26-100322.md) |
| Gross margin | % | [68.4%](/filings/0001558370-24-012430.md) | [67.7%](/filings/0001558370-25-011716.md) | [66.4%](/filings/0001104659-26-100322.md) | [64.8%](/filings/0001104659-26-100322.md) | [65.8%](/filings/0001104659-26-100322.md) |
| Operating margin | % | [26.8%](/filings/0001558370-24-012430.md) | [26.3%](/filings/0001558370-25-011716.md) | [17.8%](/filings/0001104659-26-100322.md) | [8.4%](/filings/0001104659-26-100322.md) | [20.7%](/filings/0001104659-26-100322.md) |
| Net margin | % | [24.6%](/filings/0001558370-24-012430.md) | [25.1%](/filings/0001558370-25-011716.md) | [14.5%](/filings/0001558370-25-011716.md) | [6.0%](/filings/0001558370-25-011716.md) | [15.0%](/filings/0001104659-26-100322.md) |
| Diluted EPS | $ per share | [1.66](/filings/0001558370-24-012430.md) | [1.76](/filings/0001558370-25-011716.md) | [1.05](/filings/0001104659-26-100322.md) | [0.46](/filings/0001104659-26-100322.md) | [1.16](/filings/0001104659-26-100322.md) |
| Free cash flow | $m | [280](/filings/0001558370-24-012430.md) | [216](/filings/0001558370-25-011716.md) | [236](/filings/0001104659-26-100322.md) | [257](/filings/0001104659-26-100322.md) | [263](/filings/0001104659-26-100322.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:ProfitLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tech/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $990.9m | 14,025,816 |  | Added +1,761,303 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $904.0m | 12,794,784 |  | Added +4,894,856 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $721.9m | 10,218,558 |  | Added +38,849 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $518.8m | 7,343,324 |  | Added +5,399,790 |
| [HBK INVESTMENTS L P](/funds/1011443.md) | 2026-06-30 | $482.2m | 6,825,000 |  | New +6,825,000 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $459.7m | 6,506,360 |  | Added +26,023 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $450.4m | 6,374,717 |  | Reduced −2,158,156 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $422.5m | 5,980,370 |  | Added +111,974 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $377.5m | 5,351,464 |  | Added +239,044 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $352.3m | 4,986,424 |  | Added +397,718 |

## Recent filings

[All 957 filings](/companies/tech/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-23 | 17:08 ET | [8-K](/filings/0001140361-26-037450.md) | 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-037450 |
| 2026-09-14 | 16:46 ET | [8-K](/filings/0001140361-26-036499.md) | 8.01 Other events | 0001140361-26-036499 |
| 2026-08-24 | 16:31 ET | [10-K](/filings/0001104659-26-100322.md) | Annual report, period 2026-06-30 | 0001104659-26-100322 |
| 2026-08-12 | 06:30 ET | [8-K](/filings/0001104659-26-094391.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-094391 |
| 2026-06-26 | 18:49 ET | [8-K](/filings/0001999371-26-013527.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001999371-26-013527 |
| 2026-06-25 | 08:21 ET | [8-K](/filings/0001999371-26-013429.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001999371-26-013429 |
| 2026-05-06 | 16:31 ET | [10-Q](/filings/0001104659-26-056302.md) | Quarterly report, period 2026-03-31 | 0001104659-26-056302 |
| 2026-05-06 | 06:30 ET | [8-K](/filings/0001104659-26-055887.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-055887 |
| 2026-02-11 | 16:30 ET | [8-K](/filings/0001104659-26-013412.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-013412 |
| 2026-02-04 | 16:31 ET | [10-Q](/filings/0001104659-26-010335.md) | Quarterly report, period 2025-12-31 | 0001104659-26-010335 |

## Latest annual report

[Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001104659-26-100322.md), filed Aug 24, 2026.

## Forecast league

Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/e96ad954-bc3b-4f61-9ee8-1f4caaa0be4d)

## About the filer

- CIK: 842023
- Tickers: TECH
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: MN
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.